论文部分内容阅读
目的通过前瞻性的研究四种常规检测血清肝酶与乙型肝炎相关性肝癌的风险关系,为临床诊断提供参考依据。方法前瞻性的收集2008年6月-2013年6月294例在医院治疗乙型肝炎患者临床资料,评估四种常规检测的肝酶(丙氨酸氨基转移酶[ALT],天门冬氨酸氨基转移酶[AST],碱性磷酸酶[ALP]和γ-谷氨酰胺转肽酶[GGT])与患者临床病理特征之间的关系,通过Kaplan-Meier和logistic方法分析四种肝酶的基线水平对乙型肝炎相关性肝癌发生的预测价值。结果调查294例患者中有26例在随访时间结束时发展成了肝癌,肝癌发生率为8.8%;在4种肝酶中,GGT和ALP是乙型肝炎相关性肝癌发生独立危险因素,基于ALP和GGT构建的AG模型能够有效的预测乙型肝炎患者发生肝癌的风险。结论血清GGT和ALP是乙型肝炎患者肝癌的发生预测因素。
Objective To prospectively study the relationship between four routine tests of serum liver enzymes and hepatitis B-associated hepatocellular carcinoma (HCC), so as to provide a reference for clinical diagnosis. Methods The clinical data of 294 patients with hepatitis B in the hospital from June 2008 to June 2013 were prospectively collected to evaluate the effects of four routine tests on liver enzymes (alanine aminotransferase [ALT], aspartate amino (AST), alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (GGT)) were compared with the clinicopathological features of patients. The baseline of four liver enzymes were analyzed by Kaplan-Meier and logistic methods Prediction of the occurrence of Hepatitis B-associated HCC RESULTS: Twenty-six of 294 patients developed HCC at the end of follow-up, with a HCC incidence of 8.8%. Of the four liver enzymes, GGT and ALP were independent risk factors for HCC-related HCC, based on ALP And GGT constructed AG model can effectively predict the risk of hepatitis B patients with liver cancer. Conclusions Serum GGT and ALP are predictors of hepatocellular carcinoma in hepatitis B patients.